Filing Details
- Accession Number:
- 0001193125-23-036871
- Form Type:
- 13G Filing
- Publication Date:
- 2023-02-13 19:00:00
- Filed By:
- Bcls Ii Equity Opportunities, Lp
- Company:
- Spyre Therapeutics Inc. (NASDAQ:SYRE)
- Filing Date:
- 2023-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| BCLS II Equity Opportunities | 0 | 5,347,689 | 0 | 5,347,689 | 5,347,689 | 8.7% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Rule 13d-102)
Information to be Included in Statements Filed Pursuant
to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed
Pursuant to § 240.13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 2)
Aeglea BioTherapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001
par value per share
(Title of Class of Securities)
00773J103
(CUSIP Number)
December 31, 2022
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☒ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (Act), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 00773J103 | 13G | Page 2 of 6 |
| 1 | Names of reporting persons
BCLS II Equity Opportunities, LP | |||||
| 2 | Check the appropriate box if a member of a group
(a) ☐ (b) ☐ | |||||
| 3 | SEC use only
| |||||
| 4 | Citizenship or place of organization
Delaware | |||||
| Number of shares beneficially owned by each reporting person with: | 5 | Sole voting power
0 shares of Common Stock | ||||
| 6 | Shared voting power
5,347,689 shares of Common Stock | |||||
| 7 | Sole dispositive power
0 shares of Common Stock | |||||
| 8 | Shared dispositive power
5,347,689 shares of Common Stock | |||||
| 9 | Aggregate amount beneficially owned by each reporting person
5,347,689 shares of Common Stock | |||||
| 10 | Check if the aggregate amount in Row (9) excludes certain shares
☐ | |||||
| 11 | Percent of class represented by amount in Row (9)
8.7% | |||||
| 12 | Type of reporting person
PN | |||||
| CUSIP No. 00773J103 | 13G | Page 3 of 6 |
Item 1(a). Name of Issuer
The name of the issuer to which this filing on Schedule 13G relates is Aeglea BioTherapeutics, Inc. (the Issuer).
Item 1(b). Address of Issuers Principal Executive Offices
The principal executive offices of the Issuer are located at 805 Las Cimas Parkway, Suite 100, Austin, Texas 78746.
Item 2(a). Name of Person Filing
This Schedule 13G is being filed by BCLS II Equity Opportunities, LP, a Delaware limited partnership (the Reporting Person).
Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company (BCLSI), is the manager of Bain Capital Life Sciences Investors II, LLC, a Cayman Islands limited liability company (BCLSI II), which is the general partner of Bain Capital Life Sciences Fund II, L.P., a Cayman Islands exempted limited partnership (BCLS Fund II), which is the manager of BCLS II Equity Opportunities GP, LLC, a Delaware limited liability company (BCLS II Equity GP and, together with the Reporting Person, BCLSI, BCLSI II and BCLS Fund II, the Bain Capital Life Sciences Entities), which is the general partner of the Reporting Person.
As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.
Item 2(b). Address of Principal Business Office or, if None, Residence
The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.
Item 2(c). Citizenship
The Reporting Person, BCLSI and BCLS II Equity GP are each organized under the laws of the State of Delaware. BCLSI II and BCLS Fund II are each organized under the laws of the Cayman Islands.
Item 2(d). Title of Class of Securities
The class of securities of the Issuer to which this Schedule 13G relates is Common Stock, $0.0001 par value per share (Common Stock).
Item 2(e). CUSIP Number
The CUSIP number of the Common Stock is 00773J103.
Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a
| (a) | ☐ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); | ||
| (b) | ☐ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | ||
| (c) | ☐ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | ||
| CUSIP No. 00773J103 | 13G | Page 4 of 6 |
| (d) | ☐ | Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); | ||
| (e) | ☐ | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); | ||
| (f) | ☐ | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); | ||
| (g) | ☐ | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); | ||
| (h) | ☐ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | ||
| (i) | ☐ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); | ||
| (j) | ☐ | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); | ||
| (k) | ☐ | Group, in accordance with § 240.13d-1(b)(1)(ii)(K). | ||
If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution.
Item 4. Ownership
(a) Amount beneficially owned:
As of the close of business on December 31, 2022, the Reporting Person held 5,347,689 shares of Common Stock, representing approximately 8.7% of the outstanding shares of Common Stock.
The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on 61,511,078 shares of Common Stock issued and outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022.
(b) Percent of class:
See Item 4(a) hereof.
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or direct the vote:
5,347,689
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
5,347,689
Item 5. Ownership of Five Percent or Less of a Class
Not applicable.
| CUSIP No. 00773J103 | 13G | Page 5 of 6 |
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
| CUSIP No. 00773J103 | 13G | Page 6 of 6 |
SIGNATURES
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct.
| Dated: February 14, 2023 | BCLS II Equity Opportunities, LP | |||||
| By: | BCLS II Equity Opportunities GP, LLC, | |||||
| its general partner | ||||||
| By: | Bain Capital Life Sciences Fund II, L.P., | |||||
| its manager | ||||||
| By: | Bain Capital Life Sciences Investors II, LLC, | |||||
| its general partner | ||||||
| By: | Bain Capital Life Sciences Investors, LLC, | |||||
| its manager | ||||||
| By: | /s/ Andrew Hack | |||||
| Name: Andrew Hack | ||||||
| Title: Partner | ||||||